Par Pharmaceutical has announced that its licensing partner Amide Pharmaceutical
has received FDA approval to market a generic version of Remeron, an antidepressant
made by Akzo Nobel unit Organon International.
Par said Amide will market a generic version of Organon's orally disintegrating Remeron SolTab, also know by its active ingredient mirtazapine, in 15-, 30- and 45-mg doses. Amide will begin shipping all doses of the drug shortly.